| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| Targets |
4T1 ( IC50 = 26.66 μM ); HMLE RAS Twist ( IC50 = 8.7 μM ); MDA-MB-157 ( IC50 = 22.28 μM ); MDA-MB-436 ( IC50 = 30.91 μM ); SK-BR-3 ( IC50 = 36.55 μM ); MCF-7 ( IC50 = 60 μM ); PDX-BR7 ( IC50 = 10.89 μM ); PDX-IBT ( IC50 = 11.97 μM ); PDX-BR11 ( IC50 = 18.56 μM )
|
|---|---|
| ln Vitro |
In 4T1 cells, AGX51 (0–80 μM; 24 hours) lowers the levels of ID1 protein [1]. In 4T1 cells, AGX51 (40 μM; 0-72 hours) lowers the levels of ID1 protein [1]. Genes related to 4T1 cell, ER+, HER2+, TNBC, and breast cancer PDX cell are impacted by AGX51 (40 μM; 24 h) [1]. 4-48 hours at 0–80 μM AGX51 has an impact on the 4T1 cell cycle [1]. 4T1 cells' phospho-histone H3 levels are impacted by AGX51 (40 μM; 24 h) [1]. In 4T1 cells, AGX51 (40 μM; 24 h) modifies the levels of ROS [1].
|
| ln Vivo |
AGX51 impairs the control of lung function at a dose of 50 mg/kg, taken once day for four weeks [1]. In an animal model of spontaneous tumor activity, AGX51 (15 mg/kg; i.p. twice daily for three weeks) exhibits anti-tumor effect in Luciferase-labeled 4T1 cells Balb/c mice [1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: 4T1 Cell Tested Concentrations: 40 μM Incubation Duration: 0, 2, 4, 8, 12, 24, 48 and 72 hrs (hours) Experimental Results: ID1 protein levels diminished from 4 hrs (hours) until ID1 protein at 24 hrs (hours) Total loss. Cell viability assay[1] Cell Types: 4T1 cells, HMLE RAS Twist, MDA-MB-157, MDA-MB-436, MDA-MB-231, MDA-MB-453, BT-474, MDA-MB-361, SK-BR-3, MCF-7, T47-D, PDX-BR7, PDX-IBT and PDX-BR11 Tested Concentrations: 40 μM Incubation Duration: 24 hrs (hours) Experimental Results: Inhibition of 4T1, HMLE RAS Twist, MDA-MB-157, MDA -MB-436, SK-BR-3, MCF-7, PDX-BR7, PDX-IBT and PDX-BR11 cell lines with IC50 of 26.66, 8.7, 22.28, 30.91, 36.55, 60, 10.89, 11.97 and 18.56 μM, respectively. Cell cycle analysis[1] Cell Types: 4T1 Cell Tested Concentrations: 40 μM Incubation Duration: 24 and 48 hrs (hours) Experimental Results: The affected 4T1 cells had G0/G1 phase accumulation in the cell cycle. Cell viability assay[1] Cell Types: 4T1 Cell Tested Concentrations: 40 μM Incubation Duration: 4 hrs (hours) and 24 hrs (hours) Experimental Results: Phospho-histone H3 levels were diminished in 4T1 cell |
| Animal Protocol |
Animal/Disease Models: balb/c (Bagg ALBino) mouse with luciferase-labeled 4T1 cells[1]
Doses: 50 mg/kg Route of Administration: intraperitoneal (ip) injection; 60 mg/kg twice a day; for 4 weeks Experimental Results:Inhibited lung metastasis development. Animal/Disease Models: A/J mice with AOM colon tumor model[1] Doses: 15 mg/kg Route of Administration: intraperitoneal (ip) injection; 15 mg/kg twice a day; for 3 weeks Experimental Results:Dreased the colon tumors and demonstrated anti-tumor activity in AOM colon tumor mice. |
| References |
[1]. Wojnarowicz PM, et al. Anti-tumor effects of an ID antagonist with no observed acquired resistance. NPJ Breast Cancer. 2021 May 24;7(1):58.
|
| Molecular Formula |
C₂₇H₂₉NO₄
|
|---|---|
| Molecular Weight |
431.52
|
| Exact Mass |
429.23
|
| Elemental Analysis |
C, 78.29; H, 7.27; N, 3.26; O, 11.17
|
| CAS # |
330834-54-3
|
| Appearance |
Solid powder
|
| SMILES |
CCC(=O)N(CCC(C1=CC2=C(C=C1)OCO2)C3=CC=CC=C3OC)CC4=CC=CC=C4
|
| InChi Key |
SRADCMOCDMFMPS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H29NO4/c1-3-27(29)28(18-20-9-5-4-6-10-20)16-15-22(23-11-7-8-12-24(23)30-2)21-13-14-25-26(17-21)32-19-31-25/h4-14,17,22H,3,15-16,18-19H2,1-2H3
|
| Chemical Name |
N-[3-(1,3-benzodioxol-5-yl)-3-(2-methoxyphenyl)propyl]-N-benzylpropanamide
|
| Synonyms |
AGX-51; AGX51; AGX 51
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~231.7 mM)
Ethanol: ~100 mg/mL (~231.7 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (4.82 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 5%DMSO+ 40%PEG300+ 5%Tween 80: 5.0mg/ml (11.59mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3174 mL | 11.5869 mL | 23.1739 mL | |
| 5 mM | 0.4635 mL | 2.3174 mL | 4.6348 mL | |
| 10 mM | 0.2317 mL | 1.1587 mL | 2.3174 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
